Related references
Note: Only part of the references are listed.Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
G. J. Ossenkoppele et al.
LEUKEMIA (2020)
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
Bruno C. Medeiros et al.
HAEMATOLOGICA (2018)
Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia
Bruno C. Medeiros et al.
HAEMATOLOGICA (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia
Daniel J. DeAngelo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study
Giuseppe Visani et al.
LEUKEMIA RESEARCH (2017)
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML
Bob Lowenberg et al.
BLOOD (2017)
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome
Rupa Narayan et al.
LEUKEMIA & LYMPHOMA (2016)
A phase I study of intermediate dose cytarabine in combination with lenalidomide in relapsed/refractory acute myeloid leukemia
Elizabeth A. Griffiths et al.
LEUKEMIA RESEARCH (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
Daniel A. Pollyea et al.
HAEMATOLOGICA (2013)
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML
G. Ramsingh et al.
LEUKEMIA (2013)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
D. A. Pollyea et al.
LEUKEMIA (2012)
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia
Todd A. Fehniger et al.
BLOOD (2011)
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605
Mikkael A. Sekeres et al.
BLOOD (2011)
Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias
William Blum et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mechanism of action of lenalidomide in hematological malignancies
Venumadhav Kotla et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Monosomal karyotype in acute myeloid leukemia:: A better indicator of poor prognosis than a complex karyotype
Dimitri A. Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Share Paper
